Seeking Alpha
17 Jun 2026, 10:33 UTC · 21w ago
AbCellera: An AI-Era Antibody Platform Trading For Little More Than Its Cash
Impact · against what's priced in
AbCellera appears undervalued based on its current liquidity and platform assets, with a significant near-term catalyst in the form of Phase 2 data. The market is currently valuing the company close to its cash position, effectively ignoring the potential of its AI discovery engine and royalty portfolio.
- ABCL+0.70
No priced-in read yet
- In context
The combination of $650M in liquidity against a $1.6B market cap and an upcoming Phase 2 data readout provides a strong valuation floor and a primary catalyst for price appreciation.
Read from the article alone

Search tags




